From:
`To:
`Cc:
`Subject:
`Date:
`
`Trials
`Snedden, Sheridan; Paulraj, Christopher; Hulse, Tina
`Trials
`FW: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132
`Thursday, March 30, 2017 6:32:36 AM
`
`Please see below
`
`Thanks
`Andrew
`
`From: Dorothy Whelan [mailto:whelan@fr.com]
`Sent: Thursday, March 30, 2017 9:22 AM
`To: Trials <Trials@USPTO.GOV>
`Cc: sparmelee@wsgr.com; mrosato@wsgr.com; jmills@wsgr.com; IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; PTAB Inbound
`<PTABInbound@fr.com>; Michael Kane <kane@fr.com>; dmazzochi@rmmslegal.com; jpolivick@rmmslegal.com; pabbott@rmmslegal.com;
`gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; Ribar, Travis B.
`<tribar@sughrue.com>; PCurtin@rmmslegal.com
`Subject: RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132
`
`
`
`Patent Owner does not intend to file Preliminary Responses to the Teva and Akorn Petitions.
`
`Regards,
`Dorothy Whelan
`Counsel for Patent Owner, Allergan, Inc.
`
`From: Trials [mailto:Trials@USPTO.GOV]
`Sent: Wednesday, March 29, 2017 11:50 AM
`To: Trials <Trials@USPTO.GOV>; Dorothy Whelan <whelan@fr.com>
`Cc: sparmelee@wsgr.com; mrosato@wsgr.com; jmills@wsgr.com; IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; PTAB Inbound
`<PTABInbound@fr.com>; Michael Kane <kane@fr.com>; dmazzochi@rmmslegal.com; jpolivick@rmmslegal.com; pabbott@rmmslegal.com;
`gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; Ribar, Travis B.
`<tribar@sughrue.com>; PCurtin@rmmslegal.com
`Subject: RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132
`
`Counsel,
`
`Following our telephone conference yesterday, the panel seeks further clarification from Patent Owner regarding whether it intends to file Preliminary
`Responses to the Teva and Akorn Petitions, or if Patent Owner waives those Preliminary Responses.
`
`Patent Owner, please respond to this email by close of business on Monday, April 3, 2017.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`
`
`From: Trials
`Sent: Tuesday, March 28, 2017 10:12 AM
`To: Dorothy Whelan <whelan@fr.com>; Trials <Trials@USPTO.GOV>
`Cc: sparmelee@wsgr.com; mrosato@wsgr.com; jmills@wsgr.com; IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; PTAB Inbound
`<PTABInbound@fr.com>; Michael Kane <kane@fr.com>; dmazzochi@rmmslegal.com; jpolivick@rmmslegal.com; pabbott@rmmslegal.com;
`gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; Ribar, Travis B.
`<tribar@sughrue.com>; PCurtin@rmmslegal.com
`Subject: RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132
`
`Counsel,
`
`The call will be today at 12:00 pm EST. The dial in number is 877-476-3810 and the passcode is 8984275.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`
`

`

`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`
`
`From: Dorothy Whelan [mailto:whelan@fr.com]
`Sent: Monday, March 27, 2017 5:10 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: sparmelee@wsgr.com; mrosato@wsgr.com; jmills@wsgr.com; IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; PTAB Inbound
`<PTABInbound@fr.com>; Michael Kane <kane@fr.com>; dmazzochi@rmmslegal.com; jpolivick@rmmslegal.com; pabbott@rmmslegal.com;
`gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; Ribar, Travis B.
`<tribar@sughrue.com>; PCurtin@rmmslegal.com
`Subject: RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132
`
`
`
`Dear Board: Could you please advise whether the panel is available for a teleconference on Tuesday, March 28 at 12 pm EST for a
`teleconference? Thank you for your consideration.
`
`Regards,
`Dorothy Whelan
`Counsel for Patent Owner, Allergan, Inc.
`
`From: Dorothy Whelan
`Sent: Wednesday, March 22, 2017 6:50 AM
`To: Trials <Trials@USPTO.GOV>
`Cc: sparmelee@wsgr.com; mrosato@wsgr.com; jmills@wsgr.com; IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; PTAB Inbound
`<PTABInbound@fr.com>; Michael Kane <kane@fr.com>; dmazzochi@rmmslegal.com; jpolivick@rmmslegal.com; pabbott@rmmslegal.com;
`gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; Ribar, Travis B.
`<tribar@sughrue.com>; PCurtin@rmmslegal.com
`Subject: Re: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132
`
`Dear Board: The parties have conferred and propose Tuesday, March 28 at 12 pm eastern standard time for a teleconference.
`
`Regards
`Dorothy Whelan
`Counsel for patent owner, Allergan, Inc
`
`Sent from my iPhone
`
`On Mar 20, 2017, at 3:34 PM, Trials <Trials@USPTO.GOV> wrote:
`
`Counsel,
`
`The panel requests a teleconference among Patent Owner Allergan, Inc. and Petitioners Famy Care Limited (“FCL”) and Mylan
`Pharmaceuticals to discuss FCL’s motion for joinder filed in IPR2017-00566, -00567, -00568, -00569, -00570, and -00571. The panel
`is inclined to grant the motions for joinder, but would like to discuss various procedural issues with the parties, including the case
`schedule and proposals for supplemental briefing, if any. Petitioners Teva Pharmaceuticals USA, Inc. and Akorn, Inc., who have also
`filed motions for joinder, may join the call if they would like, but their attendance is not required.
`
`The panel is available on Friday, March 24, at 1 pm ET. Should the parties not be available at this time, the panel requests that the
`parties confer and propose a time between 12 PM and 2 PM ET on any day between March 27th to March 31st.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`
`****************************************************************************************************************************
`This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged
`information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the
`
`

`

`sender by reply email and destroy all copies of the original message.
`****************************************************************************************************************************
`
`****************************************************************************************************************************
`This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged
`information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the
`sender by reply email and destroy all copies of the original message.
`****************************************************************************************************************************
`
`